Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Paul M. Ridker; Francisco Antônio Helfenstein Fonseca; Jacques Genest; Antonio M. Gotto; John J.P. Kastelein; Nardev S. Khurmi; Wolfgang Köenig; Peter Libby; Alberto Lorenzatti; Børge G. Nordestgaard; James Shepherd; James T. Willerson; Robert J. Glynn

doi:10.1016/j.amjcard.2007.09.072

Keywords

RosuvastatinMedicineStatinInternal medicineC-reactive proteinPlaceboCholesterolRosuvastatin CalciumRandomized controlled trialInterquartile rangeGastroenterologyInflammationPathology

Affiliated Institutions

Related Publications

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Paul M. Ridker , Eleanor Danielson , Francisco Antônio Helfenstein Fonseca +11 more

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence...

2008 New England Journal of Medicine 6445 citations

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Paul M. Ridker , Nader Rifai , Michael Clearfield +4 more

Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

2001 New England Journal of Medicine 1545 citations

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Scott M. Grundy , James I. Cleeman , C. Noel Bairey Merz +6 more

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the pub...

2004 Circulation 6899 citations

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Erin A. Bohula , Robert P. Giugliano , Christopher P. Cannon +6 more

Background— Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C an...

2015 Circulation 327 citations

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun , D. J. Betteridge , Paul N. Durrington +7 more

2004 The Lancet 3751 citations

Publication Info

Year: 2007
Type: article
Volume: 100
Issue: 11
Pages: 1659-1664
Citations: 125
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

125

OpenAlex

Cite This

APA Style

                            
                                
                                    Paul M. Ridker, 
                                
                                    Francisco Antônio Helfenstein Fonseca, 
                                
                                    Jacques Genest
                                
                                et al.
                            
                            (2007). 
                            Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. 
                            The American Journal of Cardiology
                            , 100
                            (11)
                            , 1659-1664.
                            https://doi.org/10.1016/j.amjcard.2007.09.072
                        

Identifiers

DOI: 10.1016/j.amjcard.2007.09.072